All News
Safety and Tolerability of Subcutaneous Methotrexate
A large, single-rheumatology center analysis of oral and subcutaneous (SC) methotrexate (MTX) use in daily clinical practice suggests that SC MTX has fewer drug discontinuations and is better tolerated compared to other DMARD therapies.
Read Article
Delays in Joint Replacement as JIA Patients Reach Adulthood
A retrospective cohort study examined the need for joint replacement surgery in juvenile idiopathic arthritis (JIA) and showed there has been a trend to delay arthroplasty over time. The JIA category, year of implant, and presence of complications significantly affected implant survivorship.
Read Article
Rheumatic Flares Uncommon After COVID Vax
Post-vaccination disease flares were uncommon among patients with rheumatic and musculoskeletal diseases who were inoculated against COVID-19, researchers found.
Read Article
Multimorbidity Impairs Responses in Rheumatoid Arthritis
A retrospective analysis of the ACR RISE registry shows that multimorbidity is not only common in patients with active rheumatoid arthritis (RA), but also impacts treatment choices and outcomes.
Read Article
Rheumatoid Arthritis Offspring Show Normal School Performance
A prospective, longitudinal study of the cognitive development of children born to mothers with rheumatoid arthritis (RA) demonstrates normal development as measured by comparative school test scores.
Read Article
Fibromyalgianess Influences Steroid Persistence
"Fibromyalgianess" is highlighted as a risk factor for undue, extended glucocorticoid use in rheumatoid arthritis (RA) patients, according to Wallace and colleagues in Rheumatology.
Read Article
RheumNow Podcast – Psoriatic Arthritis Without Psoriasis (7.30.2021)
How much psoriasis do you need to have in order to have psoriatic arthritis? This plus a review of rheumatology and COVID news from the past week on RheumNow.com.
Read Article
Shingles Risk with JAK Inhibitors and Other Biologics
Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.
Read Article
No Cancer Risk with TNF Inhibitors in Rheumatoid Arthritis
The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs).
Read Article
Combo Methotrexate and Leflunomide Safety in RA
Methotrexate and leflunomide (LEF) are the most widely prescribed DMARDs worldwide; yet biologic DMARDs are the newest and best selling agents for rheumatoid arthritis worldwide.
Read Article
Cardiovascular Prevention Lacking in Rheumatoid Arthritis
An increased cardiovascular disease (CVD) risk in rheumatoid arthritis is well known and feared but an RA cohort study suggests that preventive medication use in RA patients lags behind that seen in diabetes mellitus (DM).
Read Article
US News & World Report Ranks Best Rheumatology Hospitals
Medscape has published the annual U.S.
Read Article
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
